Literature DB >> 2930066

Smear- and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy.

A K Dutt1, D Moers, W W Stead.   

Abstract

Patients with positive tuberculin reaction, abnormal chest radiograph, and negative bacteriology are often treated empirically for tuberculosis (TB) after exclusion of other causes. Therapy generally consists of two bactericidal drugs (rifampin [RIF] and isoniazid [INH]) for 9 months or INH for 9 to 12 months. With such a small bacillary population, even less therapy might suffice. Thus we began in January 1980 to discontinue therapy at 4 months when there was sufficient evidence of a paucity of bacilli demonstrated by at least three negative smears and cultures for TB at the start of therapy. To date, 452 such patients have been so treated. Radiographic abnormalities included pulmonary infiltration of varying extent, pleural residuals, and hilar adenopathy. The full course of therapy could not be completed in 38 (8.4%) patients due to death, relocation, or drug toxicity. Side effects of the drugs occurred in 21 (4.7%) patients, but toxic hepatitis occurred in only four (0.9%) patients. Thus, 414 patients completed the full 4-month course of therapy. Of these, 126 (30.4%) patients showed radiographic and/or clinical response suggesting active infection. The remainder showed no such improvement, suggesting either a mistake in diagnosis or dormant TB. During follow-up of the 414 patients from 6 to 78 months (median, 44 months), five (1.2%) patients relapsed: three among responders and two among nonresponders. Thus, among persons suspected of having TB but with negative bacteriology, 4 months of chemotherapy with INH and RIF gave results comparable to those achieved with 9 months of therapy in smear- and culture-positive cases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2930066     DOI: 10.1164/ajrccm/139.4.867

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  16 in total

1.  Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.

Authors:  José Francisco García-Rodríguez; N Valcarce-Pardeiro; H Álvarez-Díaz; A Mariño-Callejo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-03       Impact factor: 3.267

Review 2.  Revised guidelines for the diagnosis and control of tuberculosis: impact on management in the elderly.

Authors:  Paul Van den Brande
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Authors:  Zahoor Ahmad; Eric L Nuermberger; Rokeya Tasneen; Michael L Pinn; Kathy N Williams; Charles A Peloquin; Jacques H Grosset; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2010-01-31       Impact factor: 5.790

4.  Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.

Authors:  S R Salpeter
Journal:  West J Med       Date:  1993-11

Review 5.  Tuberculosis chemoprophylaxis.

Authors:  S Salpeter
Journal:  West J Med       Date:  1992-10

6.  Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

Authors:  John L Johnson; David Jamil Hadad; Reynaldo Dietze; Ethel Leonor Noia Maciel; Barrett Sewali; Phineas Gitta; Alphonse Okwera; Roy D Mugerwa; Mary Rose Alcaneses; Maria Imelda Quelapio; Thelma E Tupasi; Libby Horter; Sara M Debanne; Kathleen D Eisenach; W Henry Boom
Journal:  Am J Respir Crit Care Med       Date:  2009-06-19       Impact factor: 21.405

7.  Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.

Authors:  Anne F Luetkemeyer; Cynthia Firnhaber; Michelle A Kendall; Xingye Wu; Gerald H Mazurek; Debra A Benator; Roberto Arduino; Michel Fernandez; Elizabeth Guy; Pamela Johnson; Beverly Metchock; Fred Sattler; Edward Telzak; Yun F Wang; Marc Weiner; Susan Swindells; Ian M Sanne; Diane V Havlir; Beatriz Grinsztejn; David Alland
Journal:  Clin Infect Dis       Date:  2016-02-02       Impact factor: 9.079

8.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

Review 9.  Tuberculosis in the AIDS era.

Authors:  K A Sepkowitz; J Raffalli; L Riley; T E Kiehn; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

10.  Why is long-term therapy required to cure tuberculosis?

Authors:  Lynn E Connolly; Paul H Edelstein; Lalita Ramakrishnan
Journal:  PLoS Med       Date:  2007-03       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.